JP Morgan Chase’s Aquestive Therapeutics AQST Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $518K | Buy |
124,505
+60,067
| +93% | +$253K | ﹤0.01% | 5083 |
|
|
2026
Q1 | $260K | Sell |
64,438
-314,979
| -83% | -$1.28M | ﹤0.01% | 5340 |
|
|
2025
Q4 | $2.45M | Sell |
379,417
-94,162
| -20% | -$587K | ﹤0.01% | 3923 |
|
|
2025
Q3 | $2.65M | Buy |
473,579
+37,607
| +9% | +$163K | ﹤0.01% | 3868 |
|
|
2025
Q2 | $1.44M | Buy |
435,972
+137,956
| +46% | +$396K | ﹤0.01% | 4145 |
|
|
2025
Q1 | $864K | Buy |
298,016
+222,516
| +295% | +$674K | ﹤0.01% | 4451 |
|
|
2024
Q4 | $269K | Buy |
75,500
+30,467
| +68% | +$140K | ﹤0.01% | 5347 |
|
|
2024
Q3 | $224K | Buy |
45,033
+13,199
| +41% | +$51.4K | ﹤0.01% | 5355 |
|
|
2024
Q2 | $82.8K | Sell |
31,834
-70,585
| -69% | -$236K | ﹤0.01% | 5622 |
|
|
2024
Q1 | $436K | Buy |
102,419
+51,363
| +101% | +$171K | ﹤0.01% | 4882 |
|
|
2023
Q4 | $103K | Buy |
51,056
+50,818
| +21,352% | +$89.8K | ﹤0.01% | 5720 |
|
|
2023
Q3 | $364 | Sell |
238
-1,070
| -82% | -$1.84K | ﹤0.01% | 6767 |
|
|
2023
Q2 | $2.16K | Buy |
1,308
+1,123
| +607% | +$2.03K | ﹤0.01% | 6322 |
|
|
2023
Q1 | $0 | Hold |
185
| – | – | ﹤0.01% | 6666 |
|
|
2022
Q4 | $0 | Sell |
185
-2,262
| -92% | -$2.12K | ﹤0.01% | 6522 |
|
|
2022
Q3 | $3K | Buy |
2,447
+716
| +41% | +$809 | ﹤0.01% | 6172 |
|
|
2022
Q2 | $1K | Sell |
1,731
-164,624
| -99% | -$219K | ﹤0.01% | 6336 |
|
|
2022
Q1 | $434K | Buy |
166,355
+23,987
| +17% | +$70.1K | ﹤0.01% | 4787 |
|
|
2021
Q4 | $554K | Buy |
142,368
+23,903
| +20% | +$120K | ﹤0.01% | 4760 |
|
|
2021
Q3 | $517K | Sell |
118,465
-6,946
| -6% | -$27.2K | ﹤0.01% | 4700 |
|
|
2021
Q2 | $497K | Buy |
125,411
+88,342
| +238% | +$353K | ﹤0.01% | 4699 |
|
|
2021
Q1 | $193K | Sell |
37,069
-1,794
| -5% | -$9.54K | ﹤0.01% | 5162 |
|
|
2020
Q4 | $208K | Buy |
38,863
+25,347
| +188% | +$152K | ﹤0.01% | 4795 |
|
|
2020
Q3 | $60K | Buy |
13,516
+4,446
| +49% | +$29.1K | ﹤0.01% | 4891 |
|
|
2020
Q2 | $44K | Sell |
9,070
-404,892
| -98% | -$1.86M | ﹤0.01% | 4864 |
|
|
2020
Q1 | $907K | Buy |
413,962
+95,381
| +30% | +$362K | ﹤0.01% | 3455 |
|
|
2019
Q4 | $1.85M | Buy |
318,581
+206,778
| +185% | +$1.08M | ﹤0.01% | 3435 |
|
|
2019
Q3 | $356K | Buy |
111,803
+89,042
| +391% | +$334K | ﹤0.01% | 4338 |
|
|
2019
Q2 | $93K | Buy |
22,761
+20,014
| +729% | +$102K | ﹤0.01% | 4960 |
|
|
2019
Q1 | $19K | Buy |
2,747
+1,412
| +106% | +$9.89K | ﹤0.01% | 5417 |
|
|
2018
Q4 | $8K | Buy |
1,335
+125
| +10% | +$1.58K | ﹤0.01% | 5464 |
|
|
2018
Q3 | $21K | Buy |
+1,210
| New | +$19.9K | ﹤0.01% | 5408 |
|
Other funds holding AQST
BCM
RI
SB
SCM
JP Morgan Chase's AQST Position: Q2 2026 in Review
JP Morgan Chase increased its Aquestive Therapeutics (AQST) stake by 93% in Q2 2026, buying an estimated $253K and bringing the position to 124,505 shares worth $518K. The position accounts for ﹤0.01% of the portfolio, ranked #5083.
JP Morgan Chase first reported a position in AQST in Q3 2018 and has held it in 32 quarters since. The position peaked at $2.65M in Q3 2025. 185 funds tracked by Wall St. Rank hold AQST as of Q2 2026.
- JP Morgan Chase held 124,505 shares of Aquestive Therapeutics worth $518K as of Q2 2026.
- JP Morgan Chase bought 60,067 Aquestive Therapeutics shares in Q2 2026, an estimated $253K.
- Aquestive Therapeutics made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #5083 holding.
- JP Morgan Chase first reported a position in Aquestive Therapeutics in Q3 2018 and has held it in 32 quarters since.
- JP Morgan Chase's Aquestive Therapeutics position peaked at $2.65M in Q3 2025.
- 185 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q2 2026.
Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.